UTHR Stock Forecast 2025-2026
Distance to UTHR Price Targets
UTHR Price Momentum
10 Quality Stocks Worth Considering Now
Researching United Therapeutics (UTHR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on UTHR and similar high-potential opportunities.
Latest UTHR Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, UTHR has a bullish consensus with a median price target of $397.50 (ranging from $314.00 to $600.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $296.42, the median forecast implies a 34.1% upside. This outlook is supported by 9 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Hartaj Singh at Oppenheimer, projecting a 102.4% upside. Conversely, the most conservative target is provided by Greg Harrison at B of A Securities, suggesting a 5.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
UTHR Analyst Ratings
UTHR Price Target Range
Latest UTHR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for UTHR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $355.00 |
| Apr 21, 2025 | B of A Securities | Greg Harrison | Neutral | Upgrade | $314.00 |
| Feb 27, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $425.00 |
| Jan 8, 2025 | UBS | Ashwani Verma | Buy | Maintains | $475.00 |
| Nov 1, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $302.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $425.00 |
| Oct 31, 2024 | Argus Research | Jasper Hellweg | Buy | Maintains | $400.00 |
| Oct 31, 2024 | Ladenburg Thalmann | Matthew Kaplan | Buy | Maintains | $344.00 |
| Oct 31, 2024 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $600.00 |
| Oct 21, 2024 | TD Cowen | Joseph Thome | Buy | Maintains | $400.00 |
| Sep 23, 2024 | Jefferies | Eun Yang | Buy | Maintains | $432.00 |
| Aug 28, 2024 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $575.00 |
| Aug 20, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $380.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $400.00 |
| Aug 1, 2024 | B of A Securities | Greg Harrison | Underperform | Maintains | $280.00 |
| Jul 25, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $400.00 |
| Jul 11, 2024 | Morgan Stanley | Terence Flynn | Equal-Weight | Downgrade | $321.00 |
| Jul 11, 2024 | TD Cowen | Joseph Thome | Buy | Maintains | $350.00 |
| Jul 8, 2024 | UBS | Ashwani Verma | Buy | Maintains | $370.00 |
| Jun 12, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $350.00 |
United Therapeutics Corporation (UTHR) Competitors
The following stocks are similar to United Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
United Therapeutics Corporation (UTHR) Financial Data
United Therapeutics Corporation has a market capitalization of $13.18B with a P/E ratio of 11.9x. The company generates $2.88B in trailing twelve-month revenue with a 41.5% profit margin.
Revenue growth is +19.7% quarter-over-quarter, while maintaining an operating margin of +49.2% and return on equity of +19.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
United Therapeutics Corporation (UTHR) Business Model
About United Therapeutics Corporation
Biotechnology company developing innovative pharmaceuticals.
The company generates revenue by developing and commercializing pharmaceutical products, particularly for chronic and life-threatening conditions like pulmonary arterial hypertension (PAH). United Therapeutics offers a range of treatments including oral and inhaled options, which help improve the quality of life for patients while addressing unmet medical needs.
Headquartered in Silver Spring, Maryland, the company is engaged in all stages of drug research, from clinical trials to post-market analysis. United Therapeutics also invests in future medical technologies, including organ manufacturing and regenerative medicine, positioning itself as a key player in advancing healthcare solutions.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,305
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Country
United States
IPO Year
1999
Website
www.unither.comUnited Therapeutics Corporation (UTHR) Latest News & Analysis
Latest News
United Therapeutics Corporation (Nasdaq: UTHR) will present research at the ATS International Conference in San Francisco from May 16-21, 2025, and is sponsoring key events during the conference.
The announcement of United Therapeutics' research presentations and sponsorship at a major conference highlights its commitment to innovation, potentially boosting investor confidence and stock performance.
Zacks Style Scores can assist investors in selecting strong stocks that may outperform the market for their investment portfolios.
The Zacks Style Scores provide a systematic approach to identify high-potential stocks, which can enhance portfolio performance and drive investment returns.
The Zacks Earnings ESP tool is highlighted as a method for identifying potential earnings surprises, suggesting that investors consider using it for strategic advantage.
The Zacks Earnings ESP can identify stocks likely to exceed earnings expectations, presenting opportunities for higher returns and informed investment decisions.
United Therapeutics (UTHR) has a strong earnings surprise history and appears well-positioned for a positive outcome in its upcoming quarterly report.
United Therapeutics' strong earnings surprise history and favorable conditions suggest potential for positive earnings growth, which can boost stock performance and investor confidence.
United Therapeutics Corporation (Nasdaq: UTHR) will present ten posters and presentations at the ISHLT 45th Annual Meeting from April 27-30, 2025, in Boston, highlighting its commercial and development portfolio.
United Therapeutics' presentations at a major medical conference may indicate potential advancements in their product pipeline, influencing stock performance and investor sentiment.
United Therapeutics is rated a BUY, with strong financial growth and a positive outlook. Revenue relies on Treprostinil drugs, facing competition post-2025. Key metrics show robust growth and low debt.
United Therapeutics' strong growth metrics and low debt make it an attractive investment, even amid patent expiration risks and upcoming competition, suggesting potential for significant returns.
Frequently Asked Questions About UTHR Stock
What is United Therapeutics Corporation's (UTHR) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, United Therapeutics Corporation (UTHR) has a median price target of $397.50. The highest price target is $600.00 and the lowest is $314.00.
Is UTHR stock a good investment in 2025?
According to current analyst ratings, UTHR has 9 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $296.42. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for UTHR stock?
Wall Street analysts predict UTHR stock could reach $397.50 in the next 12 months. This represents a 34.1% increase from the current price of $296.42. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is United Therapeutics Corporation's business model?
The company generates revenue by developing and commercializing pharmaceutical products, particularly for chronic and life-threatening conditions like pulmonary arterial hypertension (PAH). United Therapeutics offers a range of treatments including oral and inhaled options, which help improve the quality of life for patients while addressing unmet medical needs.
What is the highest forecasted price for UTHR United Therapeutics Corporation?
The highest price target for UTHR is $600.00 from Hartaj Singh at Oppenheimer, which represents a 102.4% increase from the current price of $296.42.
What is the lowest forecasted price for UTHR United Therapeutics Corporation?
The lowest price target for UTHR is $314.00 from Greg Harrison at B of A Securities, which represents a 5.9% increase from the current price of $296.42.
What is the overall UTHR consensus from analysts for United Therapeutics Corporation?
The overall analyst consensus for UTHR is bullish. Out of 19 Wall Street analysts, 9 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $397.50.
How accurate are UTHR stock price projections?
Stock price projections, including those for United Therapeutics Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.